Novo Nordisk attracts lawmakers' scrutiny after dropping discounted insulin product Levemir
Novo Nordisk is receiving pushback from a trio of lawmakers over its decision to discontinue its long-acting insulin product Levemir, which was due for a steep discount at the start of the new year. In a letter (PDF) addressed to Novo’s CEO Lars Fruergaard …